New lupus drug shows promise in Mid-Stage trial
NCT ID NCT05796206
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tests a new drug called MIL62 in 120 adults with systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce lupus disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The main focus is on how many people achieve a 20% improvement in lupus symptoms after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.